Your browser doesn't support javascript.
loading
A prospective multicenter phase II study of oral and i.v. vinorelbine plus trastuzumab as first-line therapy in HER2-overexpressing metastatic breast cancer.
Heinemann, V; Di Gioia, D; Vehling-Kaiser, U; Harich, H-D; Heinrich, B; Welt, A; Ziske, C; Deutsch, G; Pihusch, R; Kölbl, H; Hegewisch-Becker, S; Michl, M; Stemmler, H J.
Afiliação
  • Heinemann V; Medical Department III, University of Munich, Munich. Electronic address: Volker.Heinemann@med.uni-muenchen.de.
  • Di Gioia D; Medical Department III, University of Munich, Munich.
  • Vehling-Kaiser U; Oncological Practice, Landshut.
  • Harich HD; Oncological Practice, Hof.
  • Heinrich B; Oncological Practice, Augsburg.
  • Welt A; Department of Medicine (Cancer Research), West German Cancer Center, University Hospital Essen, Essen.
  • Ziske C; Oncological Practice, Troisdorf.
  • Deutsch G; Department of Gynecology, Diakonissenkrankenhaus Karlsruhe, Karlsruhe.
  • Pihusch R; Oncological Practice, Rosenheim.
  • Kölbl H; Department of Gynecology, University of Mainz, Mainz.
  • Hegewisch-Becker S; Oncological Practice, Hamburg, Germany.
  • Michl M; Medical Department III, University of Munich, Munich.
  • Stemmler HJ; Medical Department III, University of Munich, Munich.
Ann Oncol ; 22(3): 603-608, 2011 Mar.
Article em En | MEDLINE | ID: mdl-20724574
Assuntos
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Idioma: En Ano de publicação: 2011 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Protocolos de Quimioterapia Combinada Antineoplásica / Receptor ErbB-2 Idioma: En Ano de publicação: 2011 Tipo de documento: Article